临床眼科杂志
臨床眼科雜誌
림상안과잡지
JOURNAL OF CLINICAL OPHTHALMOLOGY
2014年
2期
176-179
,共4页
环氧合酶-2抑制剂%塞来昔布%糖尿病%糖尿病视网膜病变%促红细胞生成素
環氧閤酶-2抑製劑%塞來昔佈%糖尿病%糖尿病視網膜病變%促紅細胞生成素
배양합매-2억제제%새래석포%당뇨병%당뇨병시망막병변%촉홍세포생성소
Diabetic retinopathy%Cyclooxygenase-2 inhibitor%Celecoxib%Erythropoietin
目的:观察塞来昔布环氧合酶-2( COX-2)选择性抑制剂引起糖尿病大鼠视网膜组织促红细胞生成素的改变,探讨其防治早期糖尿病视网膜的机制。方法40只SD雄性大鼠随机分为4组,即正常组、糖尿病组、对照组、实验组,每组10只。1%链尿佐菌素腹腔注射建立糖尿病模型,饲养3个月后,处死大鼠取视网膜,HE染色观察视网膜形态学变化,SYBR荧光实时定量PCR检测视网膜组织中COX-2、EPO mRNA表达变化。结果3个月后,HE染色糖尿病组和对照组结构出现了改变;COX-2、EPO mRNA在糖尿病组和对照组,组间两两比较,无统计学差异( P <0.05),其余各组间比较均有显著性差异( P >0.05)。结论塞来昔布能够有效促进EPO的表达,可以用于早期糖尿病视网膜病变防治。
目的:觀察塞來昔佈環氧閤酶-2( COX-2)選擇性抑製劑引起糖尿病大鼠視網膜組織促紅細胞生成素的改變,探討其防治早期糖尿病視網膜的機製。方法40隻SD雄性大鼠隨機分為4組,即正常組、糖尿病組、對照組、實驗組,每組10隻。1%鏈尿佐菌素腹腔註射建立糖尿病模型,飼養3箇月後,處死大鼠取視網膜,HE染色觀察視網膜形態學變化,SYBR熒光實時定量PCR檢測視網膜組織中COX-2、EPO mRNA錶達變化。結果3箇月後,HE染色糖尿病組和對照組結構齣現瞭改變;COX-2、EPO mRNA在糖尿病組和對照組,組間兩兩比較,無統計學差異( P <0.05),其餘各組間比較均有顯著性差異( P >0.05)。結論塞來昔佈能夠有效促進EPO的錶達,可以用于早期糖尿病視網膜病變防治。
목적:관찰새래석포배양합매-2( COX-2)선택성억제제인기당뇨병대서시망막조직촉홍세포생성소적개변,탐토기방치조기당뇨병시망막적궤제。방법40지SD웅성대서수궤분위4조,즉정상조、당뇨병조、대조조、실험조,매조10지。1%련뇨좌균소복강주사건립당뇨병모형,사양3개월후,처사대서취시망막,HE염색관찰시망막형태학변화,SYBR형광실시정량PCR검측시망막조직중COX-2、EPO mRNA표체변화。결과3개월후,HE염색당뇨병조화대조조결구출현료개변;COX-2、EPO mRNA재당뇨병조화대조조,조간량량비교,무통계학차이( P <0.05),기여각조간비교균유현저성차이( P >0.05)。결론새래석포능구유효촉진EPO적표체,가이용우조기당뇨병시망막병변방치。
Objective To observe the effect of cyclooxygenase-2 inhibitor on the expression of erythropoietin ( EPO) in diabetic rats retina and the effect of celecoxib on prevention of early diabetic retinopathy .Methods Forty SD male rats were randomly divided into four groups:the normal group , diabetes group , control group and experimental group , 10 in each group.Diabetes model was established by intraperitoneal injection of streptozotocin (STZ) (50 mg/kg).All of the rats were sacrificed at 3 months.Retinae were HE stained to observe morphological changes , and SYBR real-time fluo-rescent quantitative PCR was used to detect COX-2 and EPO mRNA expression changes .Results After 3 months, HE staining showed structural changes in diabetes group and control group .There was no difference in COX-2 or EPO mRNA expression between diabetes group and the control group ( P <0.05), but between diabetes group and other two groups ( P <0.05).Conclusions Celecoxib could effectively promote the expression of EPO , thus can be used for early preven-tion and treatment for diabetic retinopathy .